Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: A retrospective cohort study

BMJ (Online)

Volumn 343, Issue 7829, 2011, Pages

  Li, De Kun ^a   Yang, Chunmei ^a   Andrade, Susan ^b   Tavares, Venessa ^a   Ferber, Jeannette R ^a  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; ELECTRONIC MEDICAL RECORD; ETHNICITY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MATERNAL AGE; NEWBORN; OBESITY; PARITY; POPULATION RESEARCH; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROGENY; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES; CHEMICALLY INDUCED DISORDER; CONGENITAL HEART MALFORMATION; FETOMATERNAL TRANSFUSION; MATERNAL HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; RISK;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DATABASES AS TOPIC; DIABETES, GESTATIONAL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MATERNAL-FETAL EXCHANGE; OBESITY; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES;

EID: 84860581244     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5931     Document Type: Article

References (11)

1. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
2. Ratnapalan S, Koren G. Taking ACE inhibitors during pregnancy. Is it safe? Can Fam Physician 2002;48:1047-9. (Pubitemid 34823357)
3. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep 1997;46:240-2.
4. Friedman JM. ACE inhibitors and congenital anomalies. N Engl J Med 2006;354:2498-500. (Pubitemid 43855055)
5. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51. (Pubitemid 43855047)
6. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009;54:63-70.
7. Lennestal R, Otterblad OP, Kallen B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65:615-25.
8. Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J. Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care 2001;24:1547-55. (Pubitemid 33716447)
9. Kroner BA, Billups SJ, Garrison KM, Lyman AE, Delate T. Actual versus projected cost avoidance for clinical pharmacy specialist-initiated medication conversions in a primary care setting in an integrated health system. J Manag Care Pharm 2008;14:155-63. (Pubitemid 351447681)
10. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 2003;107:43-8. (Pubitemid 36070931)
11. Banhidy F, Acs N, Puho EH, Czeizel AE. Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res 2011;34:257-63.